whatsmovingnow

PCVX

Vaxcyte, Inc.

October 5, 2026 · pre-market

Rarity
11.74
Peak move
+86.03%
Float cap
$7.2B

Vaxcyte, Inc. is a clinical-stage vaccine innovation company that engineers high-fidelity vaccines against bacterial diseases. It uses its XpressCF cell-free protein synthesis platform to develop conjugate and protein vaccine candidates for adult and pediatric indications. Its pipeline includes broad-spectrum pneumococcal conjugate vaccine candidates designed to prevent invasive pneumococcal disease, pneumonia, and related infections.

Where do you see this going?

no votes yet

Voting closed at 4:00 PM ET.

What we found

4 events · 2 from SEC or newswire · 1 timed with the move
  • Timed with the moveclinical_readout

    Vaxcyte reported positive topline data from the pivotal Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, meeting all 32 prespecified co-primary immunogenicity endpoints in adults 50 and older, with noninferiority for shared serotypes versus Pfizer's Prevnar 20 (PCV20) and Merck's Capvaxive (PCV21) and superiority for three VAX-31-unique serotypes plus cross-reactive 20B; a BLA filing is planned for H1 2028, and the company hosted a webcast and conference call with a related slide presentation.

    wireglobenewswire.comWebmarketscreener.comWebreuters.comWebreuters.comWebrttnews.comSEC8-K 0001193125-26-413168Webthepharmaletter.comWebinvestors.vaxcyte.comWebbenzinga.com
  • clinical_readout

    Vaxcyte announced it will host a webcast and conference call on October 5, 2026 at 8:00 a.m. ET to present topline data from the pivotal adult Phase 3 OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.

    wireglobenewswire.comWebin.marketscreener.comWebinvestors.vaxcyte.com
  • analyst_rating

    BofA Securities analyst Jason Gerberry maintained a Buy rating on Vaxcyte (PCVX) while lowering the price target to $130 from $133.

    Webeeo.com.cn
  • insider_sale

    Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil sold 2,250 shares on October 1, 2026 at $56.65-$57.09 for about $127,513 under a pre-arranged Rule 10b5-1 trading plan, exercising 2,250 options at $5.35, after selling 10,692 shares for $624,146 in the prior three months, leaving him with about 145,435 to 145,530 shares directly held.

    SEC4 0001813798-26-000021SEC144 0001969223-26-001049Webmarketbeat.comWebbasic.10jqka.com.cnWebbasic.10jqka.com.cn